Literature DB >> 22166179

[The need for uncertainty in clinical research. Equipoise].

H C M L Catarina Rodrigues1, A J M Anke Oerlemans, P P Paul van den Berg.   

Abstract

When a randomized controlled trial (RCT) that has potentially therapeutic benefits for research subjects is conducted, the line between treatment and research is often difficult to draw. However, in order to protect the well-being and rights of prospective research subjects and to ensure that they are not subjected to harmful and pointless research, the distinction between normal care and scientific research must be thoroughly explained. There has to be clear-cut 'equipoise', i.e. uncertainty in physician, patient and investigator regarding the outcome of the study. Strong patient preference for the experimental arm of an RCT does not entail a right to have access to it, as by definition it represents an option of unproven safety or efficacy (equipoise). Only in a therapeutic context do patients have the right to receive the best available care and a right to discuss their treatment preferences with their physicians. A careful informed consent procedure that clarifies the differences between research and therapy, and that emphasizes the experimental nature of trial arms, should be in place prior to randomization.

Entities:  

Mesh:

Year:  2011        PMID: 22166179

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  A survey in the hepatopancreatobiliary community on ways to enhance patient recovery.

Authors:  Edgar M Wong-Lun-Hing; Toine M Lodewick; Jan H M B Stoot; Marc H A Bemelmans; Steven W M Olde Damink; Cornelis H C Dejong; Ronald M van Dam
Journal:  HPB (Oxford)       Date:  2012-08-26       Impact factor: 3.647

2.  Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?

Authors:  Petra C E Hissink Muller; Bahar Yildiz; Cornelia F Allaart; Danielle M C Brinkman; Marion van Rossum; Lisette W A van Suijlekom-Smit; J Merlijn van den Berg; Rebecca Ten Cate; Martine C de Vries
Journal:  BMC Med Ethics       Date:  2018-12-20       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.